Apollon Wealth Management LLC Purchases 29,932 Shares of AbbVie Inc. $ABBV

Apollon Wealth Management LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 36.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 111,977 shares of the company’s stock after acquiring an additional 29,932 shares during the quarter. Apollon Wealth Management LLC’s holdings in AbbVie were worth $25,586,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Chelsea Counsel Co. bought a new position in shares of AbbVie during the third quarter worth $26,000. Westend Capital Management LLC bought a new position in shares of AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie during the third quarter worth $31,000. Evolution Wealth Management Inc. bought a new position in shares of AbbVie during the second quarter worth $26,000. Finally, Caitlin John LLC bought a new position in shares of AbbVie during the third quarter worth $33,000. Institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ABBV shares. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Morgan Stanley upped their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Citigroup dropped their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.00.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
• Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
• Positive Sentiment: Analysts and features continue to highlight AbbVie’s successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges ‘outdated’ 340B drug discount program guidance in new lawsuit
• Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie’s guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
• Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie’s guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
• Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

AbbVie Stock Down 2.0%

ABBV stock opened at $208.22 on Friday. The firm has a 50 day moving average of $220.35 and a 200 day moving average of $224.01. The stock has a market capitalization of $368.16 billion, a PE ratio of 88.23, a price-to-earnings-growth ratio of 0.76 and a beta of 0.38. AbbVie Inc. has a 52 week low of $168.54 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.